title: Letter regarding article by Tsimikas et al, "high-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial".
authors.forename: Lambertus J
authors.initials: LJ
authors.lastname: van Tits
authors.forename: Jacqueline
authors.initials: J
authors.lastname: de Graaf
authors.forename: Anton F
authors.initials: AF
authors.lastname: Stalenhoef
mesh_terms: D000208:Acute Disease; D000936:Antigen-Antibody Complex / Q000097:blood / Q000378:metabolism; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000097:blood*; D000069059:Atorvastatin; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood; D010743:Phospholipids / Q000097:blood / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D015203:Reproducibility of Results
chemical_list: D000936:Antigen-Antibody Complex; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D006538:Heptanoic Acids; D008077:Lipoproteins, LDL; D010743:Phospholipids; D011758:Pyrroles; D011933:Reagent Kits, Diagnostic; C099252:oxidized low density lipoprotein; D000069059:Atorvastatin